Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.

Moneo V, Serelde BG, Blanco-Aparicio C, Diaz-Uriarte R, Avilés P, Santamaría G, Tercero JC, Cuevas C, Carnero A.

BMC Cancer. 2014 Apr 23;14:281. doi: 10.1186/1471-2407-14-281.

2.

Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.

Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.

Anticancer Res. 2007 Jan-Feb;27(1A):423-9.

3.

Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.

Chu S, Alexiadis M, Fuller PJ.

Gynecol Oncol. 2008 Jan;108(1):182-90. Epub 2007 Oct 29.

PMID:
18028988
4.

Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.

Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET.

Clin Cancer Res. 2003 Apr;9(4):1469-73.

5.

Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.

Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorana A, Bavieri M, Fabbri LM, Brambilla E.

J Clin Oncol. 2005 Dec 1;23(34):8774-85.

PMID:
16314638
6.

Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.

Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS.

Hum Pathol. 2005 Mar;36(3):242-9.

PMID:
15791568
7.

Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.

Kawamoto T, Akisue T, Marui T, Nakatani T, Hitora T, Fujita I, Kurosaka M, Yamamoto T.

Anticancer Res. 2004 Sep-Oct;24(5A):2675-9.

8.

Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.

Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.

Reprod Sci. 2008 Sep;15(7):673-7. doi: 10.1177/1933719108317584. Epub 2008 May 20.

PMID:
18492696
9.

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A, Carboni JM.

Cancer Res. 2009 Jan 1;69(1):161-70. doi: 10.1158/0008-5472.CAN-08-0835.

10.

Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.

Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET.

Neuroendocrinology. 2006;84(1):42-8. Epub 2006 Oct 12.

PMID:
17047316
11.

Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.

Cossu-Rocca P, Contini M, Uras MG, Muroni MR, Pili F, Carru C, Bosincu L, Massarelli G, Nogales FF, De Miglio MR.

Int J Gynecol Pathol. 2012 Nov;31(6):570-9. doi: 10.1097/PGP.0b013e31824fe289.

PMID:
23018215
12.

Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.

Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, Sicklick JK, Gibbons SJ, Farrugia G, Taguchi T, Gupta A, Rubin BP, Fletcher JA, Ramachandran A, Ordog T.

Gastroenterology. 2015 Aug;149(2):420-32.e16. doi: 10.1053/j.gastro.2015.04.006. Epub 2015 Apr 9.

13.

PDGFR-alpha as a potential therapeutic target in uterine sarcomas.

Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD.

Gynecol Oncol. 2007 Mar;104(3):524-8. Epub 2006 Oct 17.

PMID:
17049587
14.

KIT, PDGFRalpha and EGFR analysis in nephroblastoma.

Wetli SC, Leuschner I, Harms D, Rufle A, Foerster A, Bihl M, Graf N, Furtwaengler R, Paulussen M, Briner J, Aslanidis C, Schmitz G, Tornillo L, Mihatsch MJ, Zlobec I, Bruder E.

Virchows Arch. 2008 Jun;452(6):637-50. doi: 10.1007/s00428-008-0605-x. Epub 2008 May 14.

PMID:
18478259
15.

Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.

Merchant MS, Woo CW, Mackall CL, Thiele CJ.

J Natl Cancer Inst. 2002 Nov 20;94(22):1673-9.

PMID:
12441322
16.

Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.

Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, Gronchi A, Pastorino U, Pierotti MA, Pilotti S.

J Pathol. 2007 Jun;212(2):227-35.

PMID:
17471466
17.

Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.

Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schöffski P, Marynen P, Vandenberghe P, Sciot R, Debiec-Rychter M.

Cancer Res. 2010 Sep 15;70(18):7304-14. doi: 10.1158/0008-5472.CAN-10-1543. Epub 2010 Aug 4.

18.

KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.

Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA.

Oncogene. 2007 Sep 27;26(44):6386-95. Epub 2007 Apr 23.

PMID:
17452978
19.

Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.

Liegl B, Gülly C, Reich O, Nogales FF, Beham A, Regauer S.

Histopathology. 2007 Mar;50(4):448-52.

PMID:
17448020
20.

Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.

Uren A, Merchant MS, Sun CJ, Vitolo MI, Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C, Toretsky JA.

Oncogene. 2003 Apr 17;22(15):2334-42.

PMID:
12700668

Supplemental Content

Support Center